Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...
A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...
An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...
News Medical on MSN5d
Questions over safety and effectiveness of new Alzheimer's drugThe safety and effectiveness of donanemab—an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA)—is ...
An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...
A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...
A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...
Japan's health ministry has officially approved the domestic production and sale of a new drug for Alzheimer's disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback